Travere Therapeutics (NASDAQ: TVTX) reported quarterly losses of $(0.70) per share which met the analyst consensus estimate. The company reported quarterly sales of $62.90 million which beat the analyst consensus estimate of $59.70 million by 5.35 percent. This is a 69.56 percent increase over sales of $37.09 million the same period last year.